🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Spain / NCT07676591
Starting soon Not applicable

EmpowerHer: Hybrid Digital Intervention for Breast Cancer Survivors

NCT07676591 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2027-07-01
Last updated
2026-06-30

Condition(s) studied

Breast CancerCancer SurvivorsQuality of LifeExercise TherapySocial SupportMobile Applications

Investigational drug(s) / intervention(s)

EmpowerHer Hybrid Program

EmpowerHer Hybrid Program: A 12-week hybrid physical exercise and health education program. It consists of home-based structured exercise sessions delivered via a dedicated mobile application (minimum of 2 sessions per week) combined with weekly, in-person group motivational and educational sessions led by a trained local facilitator in community settings.

Study summary

The goal of this clinical trial is to learn if a 12-week hybrid exercise and education program (EmpowerHer) works to improve health-related quality of life in breast cancer survivors aged 35 to 65.

The main questions it aims to answer are:

* Does the EmpowerHer program improve the everyday quality of life of participants?
* Does the program lower fatigue, anxiety, and depression while raising physical fitness?

Researchers will compare the EmpowerHer program to usual medical care to see if the program works better to help survivors recover.

Participants will:

* Use a mobile application at home at least twice a week for structured exercise.
* Read short educational modules on the mobile application about health after cancer.
* Attend weekly in-person motivational group sessions with a program facilitator.
* Complete health and physical tests at the start, at 12 weeks, and 3 months later.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Women aged 18-65 years. * History of breast cancer. * Completed primary treatment (surgery, chemotherapy, and/or radiotherapy; adjuvant hormone therapy is permitted). * No evidence of active or metastatic disease at enrolment. * Able to provide informed consent and communicate in the local language. * Own and are able to use a smartphone. * Willing to engage in the exercise program. Exclusion Criteria: * Cognitive impairment preventing safe participation or questionnaire completion. * Uncontrolled medical conditions that contraindicate exercise (e.g., unstable cardiac disease). * Concurrently enrolled in another structured exercise or survivorship study. * Pregnant or breastfeeding.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of Physiotherapy, Faculty of Physiotherapy, University of Valencia Valencia Valencia

More University of Valencia trials in Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07676591 on ClinicalTrials.gov ↗ ← All trials in Spain